Form 8-K - Current report:
SEC Accession No. 0001370053-22-000031
Filing Date
2022-05-04
Accepted
2022-05-04 16:19:20
Documents
14
Period of Report
2022-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anab-20220504.htm   iXBRL 8-K 32467
2 EX-99.1 q12022earningsrelease.htm EX-99.1 81974
  Complete submission text file 0001370053-22-000031.txt   303194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anab-20220504.xsd EX-101.SCH 2181
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anab-20220504_def.xml EX-101.DEF 9045
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anab-20220504_lab.xml EX-101.LAB 33262
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anab-20220504_pre.xml EX-101.PRE 20806
8 EXTRACTED XBRL INSTANCE DOCUMENT anab-20220504_htm.xml XML 11001
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 22891778
SIC: 2834 Pharmaceutical Preparations